Read by QxMD icon Read


Colten Wendel, Helena Zakrzewski, Bruce Carleton, Mahyar Etminan, Frederick S Mikelberg
PURPOSE: To determine the association of post-operative topical prostaglandin analog (PGA) or topical beta-blocker use and the incidence of pseudophakic cystoid macular edema (CME). METHODS AND PATIENTS: This was a nested case control study. All adult patients who underwent cataract surgery between January 1, 2006 and December 31, 2016 and who were enrolled in the PharMetrics Plus database were eligible for inclusion. The association between post-operative topical PGAs (bimatoprost, latanoprost and travoprost/travoprost-z) or beta-blocker (betaxolol, levobunolol and timolol) use and the incidence of pseudophakic CME was assessed by conditional logistic regression...
March 2, 2018: Journal of Glaucoma
Torello Lotti, Uwe Wollina, Georgi Tchernev, Yan Valle, Jacopo Lotti, Katlein França, Francesca Satolli, Miriam Rovesti, Michael Tirant, Ilia Lozev, Ivan Pidakev, Serena Gianfaldoni
Despite the continuous introduction of innovative therapies for vitiligo, today none of them provide constant and excellent results in term of repigmentation. The authors report their experience in treating a localised form of vitiligo with a new protocol consisting in the use of a Fraxel Herbium laser, and in the following application of topical Latanoprost solution and, one day after, in lesional irradiation with UVA1 laser.
January 25, 2018: Open Access Macedonian Journal of Medical Sciences
Jose M Martinez-de-la-Casa, Francisco Perez-Bartolome, Elena Urcelay, Jose L Santiago, Javier Moreno-Montanes, Pedro Arriola-Villalobos, Jose M Benitez-Del-Castillo, Julian Garcia-Feijoo
No abstract text is available yet for this article.
February 23, 2018: Ocular Surface
Luca Agnifili, Rodolfo Mastropasqua, Vincenzo Fasanella, Lorenza Brescia, Barbara Scatena, Francesco Oddone, Leonardo Mastropasqua
PURPOSE: To investigate, using in vivo confocal microscopy (IVCM), the Meibomian gland (MG) features and conjunctival goblet cell density (GCD) in glaucomatous patients controlled with prostaglandin/timolol fixed combinations (PTFCs). METHODS: In this cross-sectional study, sixty Caucasian patients treated with PTFCs, fifteen with latanoprost+timolol (L+T) unfixed combination, and fifteen controls were enrolled. Patients underwent the Ocular Surface Disease Index (OSDI) questionnaire, tear film break-up time (BUT), corneal staining, Schirmer test I (STI), and IVCM of MGs and goblet cells (GCs)...
February 2, 2018: Journal of Glaucoma
Jessie Huang, Paula Katalinic, Michael Kalloniatis, Michael P Hennessy, Barbara Zangerl
SIGNIFICANCE: This article shows that self-tonometry can provide robust measures of diurnal intraocular pressure (IOP) and also detect changes to IOP in response to treatment within a short period of monitoring. These advances in IOP monitoring may contribute to improved management of glaucoma patients and suspects. PURPOSE: The aim of this study was to prospectively investigate the utility of rebound self-tonometry performed over several weeks for detecting diurnal IOP fluctuations in glaucoma patients and suspects and also initial response to topical treatment in glaucoma patients...
January 25, 2018: Optometry and Vision Science: Official Publication of the American Academy of Optometry
Mark Lin, Mason Schmutz, Sameh Mosaed
No abstract text is available yet for this article.
January 12, 2018: Journal of Glaucoma
Francisco J Muñoz-Negrete, Francisco Arnalich-Montiel, Francisco J Lara-Medina, Gema Rebolleda
No abstract text is available yet for this article.
March 2018: Journal of Glaucoma
Yuko Sekine, Marie Shimada, Shoko Satake, Masato Okubo, Akihiro Hisaka, Tadashi Hara, Megumi Honjo, Makoto Aihara
OBJECTIVES: To investigate the effect of excipients on latanoprost penetration into the aqueous humor with clinically available 6 products with different solutions mainly in the types and concentrations of preservatives. METHODS: In 363 patients with cataracts, we instilled 1 latanoprost drop in 1 eye before surgery. The drop was randomly selected by brand name product (A) and 5 generic products (B-F) composed with different excipients. B contains similar excipients to A...
January 11, 2018: Journal of Ocular Pharmacology and Therapeutics
Che-Yuan Kuo, Yu-Fan Chang, Yu-Bai Chou, Chih-Chien Hsu, Pei-Yu Lin, Catherine Jui-Ling Liu
INTRODUCTION: Corticosteroid treatment for uveitis can lead to delayed-onset pressure-induced interlamellar stromal keratitis (PISK), even years after laser in situ keratomileusis (LASIK).A 35-year-old man presented to our clinic after experiencing blurred vision in his left eye for 1 month. For the past month, he had been prescribed topical steroid and anti-glaucomatous medication. He had undergone LASIK for both eyes 5 years earlier, and had suffered uveitis attacks in his left eye over the last 2 years...
December 2017: Medicine (Baltimore)
Xing Xu, Yufei Yan, Zhuochao Liu, Jin Qi, Niandong Qian, Hanbing Zhou, Qi Zhou, Tianqi Wang, Ping Huang, Lei Guo, Min Jiang, Lianfu Deng
Identification of agents that inhibit osteoclast formation and function is important for the treatment of osteolytic diseases which feature excessive osteoclast formation and bone resorption. Latanoprost (LTP), an analog of prostaglandin F2α, is a medication which works to lower pressure inside the eyes. Prostaglandin F2α was reported to regulate bone metabolism, however the effect of LTP in osteoclastogenesis is still unknown. Here, we found that LTP suppressed RANKL-induced osteoclastogenesis in a dose-dependent manner as illustrated by TRAP activity and TRAP staining...
December 23, 2017: Journal of Cellular Biochemistry
Ph A Kestelyn, Ph G Kestelyn, D De Bacquer, A M Stevens
PURPOSE: To validate the hypothesis that BAK induces low-grade inflammation in the anterior chamber, we designed a study to investigate whether switching from BAK-preserved to preservative-free latanoprost in patients with primary open-angle glaucoma (POAG) would reduce the flare levels. PATIENTS: Forty-one eyes of twenty-two patients with primary open-angle glaucoma treated with BAK-preserved latanoprost for at least 6 months as monotherapy were included. Exclusion criteria included any use of topical eye drops other than latanoprost, pseudoexfoliation and pigment dispersion glaucoma, wearing of contact lenses and intraocular surgery in the past year...
December 22, 2017: International Ophthalmology
Ferdinand Rodríguez-Agramonte, Juan Carlos Jiménez, José Raúl Montes
OBJECTIVE: To describe the prevalent side effects of prostaglandin analogues (PA) in a Hispanic population and their effect on quality of life (QOL). PATIENTS AND METHODS: This is a cross-sectional study conducted in a tertiary medical facility in which patients were evaluated in a single visit. Total of 14 participants in the study, 10 women and 4 men. Ages ranged from 26-78 years old. Subjects underwent a single full Oculoplastic evaluation by two physicians; one was blinded on patient medical history and assessed for PA side effects...
December 2017: Puerto Rico Health Sciences Journal
Pir Salim Mahar, Nadeem H Butt, Syed Imtiaz Ali
PURPOSE: To determine the efficacy of locally produced Latanoprost in reducing the intraocular pressure (IOP) in patients with Primary open-angle glaucoma (POAG). DESIGN: Open-label, non-comparative, observational case study with non-probability purposive sampling. METHODS: A total of 48 patients (94 eyes) of either gender were recruited from glaucoma clinic with the diagnosis of POAG, having IOP of more than 21 mmHg. Patients were commenced on locally produced Latanoprost (Vislat 0...
December 5, 2017: International Ophthalmology
Yumi Hashimoto, Seiichi Yokoo, Tomohiko Usui, Yukiko Tsubota, Satoru Yamagami
PURPOSE: To investigate the toxicity of topical glaucoma medications using cultured stratified human corneal epithelial sheets (HCES). METHODS: HCES were exposed for 30 minutes to the following glaucoma medications: 0.1% brimonidine with sodium chlorite as the preservative, 0.005% latanoprost with 0.02% benzalkonium chloride (BAC) as the preservative, and 0.5% timolol with 0.005% BAC as the preservative. Then, cell viability and barrier function were tested by the WST-1 assay and carboxyfluorescein permeability assay, respectively...
November 13, 2017: Cornea
C Gizzi, P Torino-Rodriguez, G Belcaro, S Hu, M Hosoi, B Feragalli
OBJECTIVE: Supplementation with Mirtogenol® improves the retinal microcirculation and reduces intraocular pressure (IOP) in ocular hypertension, when administrated either alone or in association with an ophthalmic solution (latanoprost). In this study, microcirculatory parameters (perfusion of the circle of Zinn-Haller and retinal circulation) and oxidative stress were tested to assess the effects of Mirtogenol® plus traditional antihypertensive drugs in patients with elevated IOP. PATIENTS AND METHODS: 88 otherwise healthy patients with increased IOP were followed-up in a supplement registry for 12 weeks...
October 2017: European Review for Medical and Pharmacological Sciences
Abhijit Anand Mohite, Rangarajan V Prabhu, Thomas Ressiniotis
Purpose: Latanoprost has become one of the most widely prescribed topical antihypertensive medications in recent years. Yet there have been few reports of secondary iris pigment epithelial (IPE) and ciliary body (CB) cyst formation to date and none, to our knowledge, reported in eyes predisposed to primary angle closure. Methods: We report the first documented case of bilateral IPE and CB cysts in a hypermetropic patient with prior laser peripheral iridotomies (LPIs) as a rare, delayed side effect of topical Latanoprost treatment...
2017: Case Reports in Ophthalmological Medicine
Uttio Roy Chowdhury, Tommy A Rinkoski, Cindy K Bahler, J Cameron Millar, Jacques A Bertrand, Bradley H Holman, Joseph M Sherwood, Darryl R Overby, Kristen L Stoltz, Peter I Dosa, Michael P Fautsch
Purpose: Cromakalim prodrug 1 (CKLP1) is a water-soluble ATP-sensitive potassium channel opener that has shown ocular hypotensive properties in ex vivo and in vivo experimental models. To determine its mechanism of action, we assessed the effect of CKLP1 on aqueous humor dynamics and in combination therapy with existing ocular hypotensive agents. Methods: Outflow facility was assessed in C57BL/6 mice by ex vivo eye perfusions and by in vivo constant flow infusion following CKLP1 treatment...
November 1, 2017: Investigative Ophthalmology & Visual Science
Mark Lin, Mason Schmutz, Sameh Mosaed
Latanoprost, and other prostaglandin analogs, have been previously associated with increased pigmentary reactions on the periocular skin. Here, we present a patient with paradoxical depigmentation of periocular skin within 1 year of latanoprost use in both eyes. This report is the first to document such an association, and clinicians should be aware of this adverse effect and monitor for signs accordingly.
November 2017: Journal of Glaucoma
M Reza Razeghinejad
There is debate concerning whether the use of Latanoprost in early postoperative period of cataract surgery and in glaucoma patients with uveitis as it may aggravate the inflammation and results in macular edema (ME), because of blood-ocular barrier disruption. However, there is no solid evidence for disruption of blood-ocular barrier with Latanoprost and aggravation of uveitis or ME formation. Similar to pseudophakic ME, the imaging ME in cases claimed to be secondary to Latanoprost is greater than clinical ME, happens mostly in complicated surgeries, and the vast majority resolve within weeks to months with using a non-steroidal anti-inflammatory drug...
October 13, 2017: Ocular Immunology and Inflammation
Daisuke Takemoto, Tomomi Higashide, Yoshiaki Saito, Shinji Ohkubo, Sachiko Udagawa, Hisashi Takeda, Kazuhisa Sugiyama
PURPOSE: We conducted a prospective study in patients with normal-tension glaucoma (NTG) who received either isopropyl unoprostone or latanoprost. We compared the drugs in terms of their effects on intraocular pressure (IOP) and visual field loss progression over a 3-year period. STUDY DESIGN: Prospective, randomized controlled study. METHODS: We enrolled 48 patients with newly diagnosed NTG at Kanazawa University Hospital. Eligible patients were randomly allocated (1:1) to receive either unoprostone or latanoprost ophthalmic solutions...
2017: Clinical Ophthalmology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"